August 2010 www.pjonline.com With over a dozen mesalazine products available for ulcerative colitis, choosing between them can be difficult. Anja St.Clair Jones discusses some of the factors that prescribers should consider. Choice should not be based on cost alone, she says, but should take into account current management strategies and adherence Mesalazine: is changing to the cheapest really ...

Patients 101 patients who were 18–80 years of age and had symptomatic (moderate or severe) grade 2 to 4 ulcerative colitis that extended >12 cm beyond the anal margin. Exclusion criteria were Crohn’s disease, idiopathic proctitis, noninflammatory bowel diseases, stool parasites, toxins, pathogens, use of steroids within the previous month, use of immunosuppressive agents in the previous 3 month...

Higher sample throughput with more information per sample may decrease the time to market, an important driving force in today’s pharmaceutical industry [1-3]. UPLC is a new category of separation technique based upon well-established principles of liquid chromatography, which utilizes sub-2 μm particles for stationary phase. These particles operate at elevated mobile phase linear velocities to...

Sofosbuvir and simeprevir are used for the treatment of chronic hepatitis C (HCV) genotype 1. Both drugs have been well-tolerated, with diarrhea noted in 6% cases with sofosbuvir, 16% with sofosbuvir plus simeprevir, and 0% with simeprevir. No prior reports exist of colitis secondary to either drug or their combination. We report a patient with no prior history of inflammatory bowel disease who...

A 29-year-old woman with ulcerative colitis underwent total colectomy with ileal-pouch-anal canal anastomosis in 1999. After the surgery, she developed refractory pouchitis. We administered metronidazole, mesalamine and ciprofloxacin; however, her clinical symptoms improved only very slightly. We initiated treatment with infliximab in June 2011 and discontinued the antibiotics. Thereafter, the ...